Effect of drug-induced hyperuricaemia on renal function in Nigerians with pulmonary tuberculosis.
Some anti-tuberculosis chemotherapeutic agents have been established as causing hyperuricaemia. Hyperuricaemia in turn causes renal damage. This study therefore aims at establishing the effect of anti-tuberculosis drugs-induced hyperuricaemia on renal function of the patients. Fifty patients with newly diagnosed pulmonary tuberculosis with mean age of 36.8 years (SD 13.69) consisting of 14 females and 17 males were longitudinally studied each for 6 months to determine the effect of drug-induced hyperuricaemia on their renal function. The Biochemical indices determined included serum urate level, serum creatinine level, and creatinine clearance of newly diagnosed patient with tuberculosis, before and during treatment with anti-tuberculosis therapy. Serum urate level revealed that 16 (51.6%) and 15 (48.4%) of the patients were hyperuricaemic at the end of the first and second months of anti-tuberculosis therapy. There was no significant difference in the mean serum creatinine level of the control group 96 micromol/L when compared with both the pre-treat value 89 micromol/L (P > 0.25) as well as the value at the end of the sixth month of treatment 91 micromol/L (P > 0.40). However, there was a statistically significant difference in the mean creatinine clearance of the control group 102 ml/min/1.73 m2 when compared with the patient's mean pre-treatment value (89 ml/min/1.73 m2) P < 0.05. Also the mean creatinine clearance increased to (103 ml/min/1.73 m2) by the end of the 6th month of treatment, a value that is statistically significant when compared with the pretreatment value of (89 ml/min/1.73 m2) P < 0.05. We submit as follows: that pulmonary tuberculosis as a disease with significant impairment of renal function; despite the associated drug-induced hyperuricaemia recorded during the treatment, renal function steadily improved with the treatment of pulmonary tuberculosis to the extent that comparable values with control was obtained at the end of treatment. We conclude therefore that drug-induced hyperuricaemia associated with treatment of pulmonary tuberculosis has no detectable negative effect on renal function of the patient.
Adebisi
S A
SA
Department of Chemical Pathology & Immunology, University of Ilorin, Nigeria.
Oluboyo
P O
PO
Okesina
A B
AB
D000328:Adult; D000995:Antitubercular Agents / Q000009:adverse effects*; D016022:Case-Control Studies; D003404:Creatinine / Q000097:blood / Q000378:metabolism; D016903:Drug Monitoring; D004359:Drug Therapy, Combination; D004977:Ethambutol / Q000009:adverse effects; D005260:Female; D006801:Humans; D007538:Isoniazid / Q000009:adverse effects; D007674:Kidney Diseases / Q000139:chemically induced* / Q000175:diagnosis / Q000378:metabolism*; D007677:Kidney Function Tests; D008137:Longitudinal Studies; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D009549:Nigeria; D011718:Pyrazinamide / Q000009:adverse effects; D012293:Rifampin / Q000009:adverse effects; D016896:Treatment Outcome; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*; D014527:Uric Acid / Q000378:metabolism*
D000995:Antitubercular Agents; D014527:Uric Acid; D011718:Pyrazinamide; D004977:Ethambutol; D003404:Creatinine; D007538:Isoniazid; D012293:Rifampin